Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
A new clinical trial is testing the combination of venetoclax with obinutuzumab and magrolimab for relapsed / refractory B-cell lymphomas.
Most resistance mutations acquired by CLL patients during zanubrutinib treatment occurred at a single site on BTK.
May 2023 CLL Bloodline: The CLL Society Bloodline will teach the BASICS needed to understand CLL.
Venetoclax monotherapy is effective for treating relapsed / refractory CLL, including in patients previously treated with BTK or PI3K inhibitors.
A combination of ibrutinib plus venetoclax is a very effective first-line treatment for CLL, and 90% of patients are progression-free after five years.
MRD guided acalabrutinib, venetoclax and obinutuzumab led to an 88% progression free survival rate in relapsed / refractory chronic lymphocytic leukemia.
When diagnosed with CLL in 2005 and told there was no cure and no treatments that even prolonged life, I decided to explore integrative oncology approaches.
Chimeric antigen receptor T-cell (CAR-T) therapy can provide durable remissions in a subset of patients with Richter’s transformation.
Pirtobrutinib is a useful treatment option to temporarily manage Richter’s transformation, but long-term treatments are still needed.
One click to our most popular content.
